Who are Ligustrazine by mouth's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ligustrazine by intravenously administration.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ligustrazine-by-mouth.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ligustrazine by mouth — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ligustrazine by mouth (Ligustrazine by mouth) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent / Vasodilator. Area: Cardiovascular.

marketed Antiplatelet agent / Vasodilator Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ligustrazine by mouth (Ligustrazine by mouth) — Shenzhen Kangning Hospital. Ligustrazine inhibits platelet aggregation and improves microcirculation by reducing blood viscosity and enhancing blood flow.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ligustrazine by mouth TARGET	Ligustrazine by mouth	Shenzhen Kangning Hospital	marketed	Antiplatelet agent / Vasodilator
Ligustrazine by intravenously administration	Ligustrazine by intravenously administration	Shenzhen Kangning Hospital	marketed	Antiplatelet agent / Vasodilator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent / Vasodilator class)

Shenzhen Kangning Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ligustrazine by mouth — Competitive Intelligence Brief. https://druglandscape.com/ci/ligustrazine-by-mouth. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab